ruxolitinib
ruxolitinib is listed in the FDA National Drug Code directory with 27 NDC codes, marketed under brand names including JAKAFI XR, JAKAFI, OPZELURA. Available dosage forms: tablet, extended release, tablet, cream.
Drug Details
- Generic Name
- ruxolitinib
- Brand Names
- JAKAFI XR, JAKAFI, OPZELURA
- Application Number
- NDA217180
- Sponsor
- Incyte Corporation
- NDC Codes
- 27
- Dosage Forms
- TABLET, EXTENDED RELEASE, TABLET, CREAM
- Routes
- ORAL, TOPICAL
- Active Ingredients
- RUXOLITINIB, RUXOLITINIB PHOSPHATE
Indications and Usage
1 INDICATIONS AND USAGE LEQSELVI™ is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants. LEQSELVI is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata. ( 1 ) Limitations of Use: LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1 )